Company intelligence / Profile preview
ImmunoSphere
- Ownership
- Private
- Development stage
- Other
Overview
ImmunoSphere is a biotechnology company specializing in the development of personalized cancer immunotherapies, specifically neoantigen-based vaccines. As a spin-off from Chulalongkorn University in Thailand, the company leverages a proprietary computational platform to identify patient-specific tumor mutations and design tailored vaccines. Their approach aims to stimulate a robust T-cell response against cancer cells while minimizing off-target toxicity. ImmunoSphere's lead programs are currently in the pre-clinical stage, with a focus on treating various solid tumors including melanoma and lung cancer. The company represents a significant advancement in the regional deep-tech ecosystem, aiming to provide accessible precision medicine solutions.
- Therapeutic areas
- Oncology
- Modalities
- VaccinePeptidesmRNA-based drugs
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on ImmunoSphere.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoSphere.